tiprankstipranks
NervGen Pharma (NGEN)
NASDAQ:NGEN
US Market
NGEN
NervGen Pharma
RESEARCH TOOLSreports

NervGen Pharma (NGEN) Stock News & Sentiment

84 Followers
NervGen Wins FDA Alignment for Phase 3 RESTORE Trial in Chronic Tetraplegia
Premium
Company Announcements
NervGen Wins FDA Alignment for Phase 3 RESTORE Trial in Chronic Tetraplegia
5d ago
NGEN
NervGen Pharma: Buy Rating on De‑Risked Path to Pivotal NVG-291 Trials and Compelling Risk‑Reward in Chronic Spinal Cord Injury
Premium
Ratings
NervGen Pharma: Buy Rating on De‑Risked Path to Pivotal NVG-291 Trials and Compelling Risk‑Reward in Chronic Spinal Cord Injury
10d ago
NGEN
NervGen Maps Path to Phase 3 as NVG-291 Data Strengthen Neuroreparative Ambitions
Premium
Company Announcements
NervGen Maps Path to Phase 3 as NVG-291 Data Strengthen Neuroreparative Ambitions
11d ago
NGEN
NervGen Pharma to Delist from TSX Venture Exchange, Keep Nasdaq Listing as NVG-291 Advances
Premium
Company Announcements
NervGen Pharma to Delist from TSX Venture Exchange, Keep Nasdaq Listing as NVG-291 Advances
1M ago
NGEN
NervGen Pharma CFO to Retire as Company Advances Late-Stage SCI Program
Premium
Company Announcements
NervGen Pharma CFO to Retire as Company Advances Late-Stage SCI Program
2M ago
NGEN
NervGen Pharma Confirms Adam Rogers as CEO With New Equity-Rich Employment Deal
Premium
Company Announcements
NervGen Pharma Confirms Adam Rogers as CEO With New Equity-Rich Employment Deal
2M ago
6K
NGEN
NervGen Pharma Confirms Adam Rogers as CEO to Steer Next Growth Phase
Premium
Company Announcements
NervGen Pharma Confirms Adam Rogers as CEO to Steer Next Growth Phase
2M ago
NGEN
More NGEN News >

NGEN News on the Web

NervGen Pharma price target raised to $12 from $10 at Maxim
TipRanks News
Neutral
NervGen Wins FDA Alignment for Phase 3 RESTORE Trial in Chronic Tetraplegia
TipRanks News
Bullish
NervGen Pharma aligns with FDA on RESTORE study following End-of-Phase 2 meeting
TipRanks News
Bullish
NervGen Pharma price target lowered to $5.50 from $6.75 at Stifel
TipRanks News
Neutral
Analysts Offer Insights on Healthcare Companies: Milestone Scientific (MLSS) and NervGen Pharma (NGEN)
TipRanks News
Bullish
NervGen Pharma: Buy Rating on De‑Risked Path to Pivotal NVG-291 Trials and Compelling Risk‑Reward in Chronic Spinal Cord Injury
TipRanks News
Neutral
NervGen Maps Path to Phase 3 as NVG-291 Data Strengthen Neuroreparative Ambitions
TipRanks News
Neutral
NervGen Pharma to Delist from TSX Venture Exchange, Keep Nasdaq Listing as NVG-291 Advances
TipRanks News
Neutral

News Score - Last 7 Days

Positive
NGEN
Sector Average
Media Buzz
This Week4 articles
Weekly Average1.75 articles
News Sentiment
This Week100%
Sector Average68%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is NGEN’s Media Buzz Sentiment?
4 articles about NGEN were published this week. In an average week, 1.75 articles are published.
    What is NGEN’s weekly average amount of articles?
    In an average week, 1.75 articles about NGEN are published.
      What is NGEN’s News Sentiment?
      100% of articles about NGEN were positive this week, compared to its sector average of 68%.
        Healthcare Stocks that are Trending in the News
        AORTArtivion
        NBIXNeurocrine
        STAAStaar Surgical
        SLPSimulations Plus
        OWLTOwlet
        Showing the stocks with the most bullish news sentiment over the past week